Rare before age 50, the incidence of prostate cancer increases progressively with age.
Several Treatment Options
Prostate cancer has a good to very good prognosis and a high survival rate. Several treatment options are offered to patients depending on their individual circumstances (type of smoker, location, stage of the disease): active surveillance, surgery, external beam radiation therapy, stereotactic radiotherapy, brachytherapy, hormone therapy, etc.
Improving Patient Care
In all these therapeutic areas, as well as during diagnosis, clinical research, and more fundamental research, the teams at the Curie Institute are constantly working to improve patient care.
Nuclear Medicine Technology
Among the therapies offered to treat prostate cancer, targeted internal radiation therapy (TIR) is one of the options when the cancer is metastatic. Unlike conventional external beam radiation therapy, this nuclear medicine technology involves intravenous injections of low-level radioactive molecules that bind specifically to tumor cells to destroy them.
Sectorized Internal Radiation Therapy
Since mid-October 2024, this IRT (Internal Radiation Therapy) activity has been offered at the Institut Curie hospital in Saint-Cloud for patients with metastatic prostate cancer after chemotherapy, as part of an early access program.
 Didier Galibert
|
28/10/2024 | 
Anglais
Français
Español
Italien
Português